Kent B Thuduim

Title: Kent B Thuduim: Innovator in Monoclonal Antibodies

Introduction

Kent B Thuduim is a notable inventor based in Oakland, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 2 patents to his name, Thuduim's work has the potential to impact various medical treatments.

Latest Patents

Thuduim's latest patents focus on human monoclonal antibodies to BTLA and methods of use. The present disclosure provides isolated monoclonal antibodies that specifically bind to BTLA with high affinity. It includes nucleic acid molecules encoding these antibodies, expression vectors, host cells, and methods for expressing the antibodies. Additionally, the patents cover immunoconjugates, bispecific molecules, and pharmaceutical compositions that comprise the antibodies. The disclosure also outlines methods for detecting BTLA and treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Career Highlights

Kent B Thuduim is associated with Medarex Inc., a company known for its innovative approaches in the field of immunotherapy. His work at Medarex has allowed him to explore and develop groundbreaking technologies that contribute to advancements in medical science.

Collaborations

Thuduim has collaborated with notable colleagues such as Alan J Korman and Mark J Selby. These partnerships have fostered an environment of innovation and creativity, leading to significant advancements in their respective fields.

Conclusion

Kent B Thuduim is a distinguished inventor whose work in monoclonal antibodies is paving the way for new treatments in medicine. His contributions are vital to the ongoing research and development in biotechnology.